Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ
Quarter End | 12 2022 | 3 2023 | 6 2023 | 9 2023 | 12 2023 | 3 2024 | 6 2024 | 9 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
総売上 | 27.05M | 43.98M | 26.37M | 34.99M | 28.1M | 30.98M | 41.53M | 51.81M |
営業利益 | 12.18M | 14.21M | -1.98M | 3.08M | -3.36M | 2.99M | -19.1M | 10.96M |
税引前収入 | 55.93M | 55.54M | 3.17M | -12.14M | 17.1M | 113.45M | -65.39M | -6.34M |
純利益 | -17.49M | 41.95M | 2.29M | -10.27M | 18.19M | 86.14M | -51.91M | -7.17M |
優先配当 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
基本的1株当たり利益 (EPS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBIT | 10.9M | 14.81M | -2.86M | -1.22M | 1.38M | 600k | -48.33M | 162k |
EBITDA | 9.81M | 23.7M | 24.59M | -4.47M | 4.63M | 11.75M | 16.24M | 19.95M |
年末 2023年12月31日 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
総売上 | 108.97M | 141.1M | 251.45M | 120.28M | 186.42M | 314.73M | 196.25M | 131.31M |
営業利益 | 40.55M | 66.03M | 213.91M | -5.72M | 8.73M | 78.9M | 3.04M | 9.82M |
税引前収入 | 7.96M | 57.23M | 173.33M | 796.64M | -10.54M | 47.3M | 36.01M | 63.66M |
純利益 | -1.64M | 12.56M | 143.32M | 629.3M | -2.99M | 57.14M | -33.36M | 52.15M |
優先配当 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
基本的1株当たり利益 (EPS) | -0.078 | 0.594 | 6.902 | 37.407 | -0.186 | 3.408 | -1.968 | 2.991 |
EBIT | 20.14M | 68.63M | 207.61M | 801.07M | 25.74M | 70.04M | 7.22M | 9.99M |
EBITDA | 51.39M | 78.55M | 230.61M | 38.01M | 36.25M | 129.96M | 41.07M | 46.34M |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約